Aurobindo Pharma Ltd share price logo

Aurobindo Pharma Ltd Share Price

(AUROPHARMA)

₹1257.80.88%

as on 04:01PM, 24 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Aurobindo Pharma Performance

  • Day's Low

    Day's High

    ₹1,239.8
    Day's Price Range
    ₹1,278.6
  • 52 Week's Low

    52 Week's High

    ₹1,010
    52-Week Price Range
    ₹1,592
1 Month Return+ 5.26 %
3 Month Return+ 6.93 %
1 Year Return+ 13.99 %
Previous Close₹1,246.80
Open₹1,246.80
Volume13.38L
Upper Circuit₹1,371.40
Lower Circuit₹1,122.20
Market Cap₹73,699.36Cr

Aurobindo Pharma Fundamentals

P/E Ratio

21.05

PEG Ratio

1.68

Market Cap

₹73,699.36 Cr

P/B Ratio

3.24

EPS

54.09

Dividend Yield

0.41

Sector

Pharmaceuticals

ROE

10.35

Aurobindo Pharma Analyst Rating

based on 28 analysts

BUY

78.57%

Buy

7.14%

Hold

14.29%

Sell

Based on 28 analysts offering long term price targets for Aurobindo Pharma. An average target of ₹1470.82

Source: S&P Global Market Intelligence

Aurobindo Pharma Share analysis

Aurobindo Pharma price forecast by 28 analysts

Upside of16.94%

High

₹1930

Target

₹1470.82

Low

₹1140

Aurobindo Pharma target price ₹1470.82, a slight upside of 16.94% compared to current price of ₹1257.8. According to 28 analysts rating.

Source: S&P Global Market Intelligence

Key events for Aurobindo Pharma Ltd

  • Aurobindo Pharma Secures USFDA Approval for Dasatinib - 23 Apr, 2025

    Aurobindo Pharma's subsidiary, Eugia Pharma, received USFDA approval for Dasatinib Tablets, a leukemia treatment, expected to launch in FY26, targeting a $1.8 billion market.
  • Aurobindo Pharma Stock Shows Strong Momentum - 22 Apr, 2025

    Aurobindo Pharma's stock has risen over 14% from a recent low of ₹1,050, currently trading at ₹1,200. It remains above its 100-DMA for two consecutive sessions, supported by positive momentum indicators.
  • Aurobindo Pharma Gains USFDA Approval for Rivaroxaban - 12 Apr, 2025

    Aurobindo Pharma has received USFDA approval for Rivaroxaban Tablets USP, 2.5 mg, with a market potential of $447 million. Tentative approvals for higher strengths could lead to a total market size of $8.5 billion, enhancing Aurobindo's position in the US market.
  • Aurobindo Pharma Faces FDA Scrutiny Amid Trial Success - 11 Apr, 2025

    Aurobindo Pharma shares surged 5% following positive Phase 1 trial results for BP16, while the company also faced FDA scrutiny at its North Carolina plant, receiving a Form 483 with 11 observations. The company is committed to addressing these observations without expecting material impact on operations.
  • Aurobindo Pharma Completes Phase 1 Trials for BP16 - 10 Apr, 2025

    Aurobindo Pharma's subsidiary, CuraTeQ Biologics, successfully completed Phase 1 trials for BP16, a new bone treatment. However, the stock has declined 9% weekly and 22-23% year-to-date.
  • Aurobindo Pharma Faces Tariff Threats Amid Drug Success - 09 Apr, 2025

    On April 9, Aurobindo Pharma faced a stock decline due to Trump's tariff threats while also reporting successful Phase 1 trial results for osteoporosis drug BP16.
  • Aurobindo Pharma Gains EU Approval Amid Profit Decline - 07 Apr, 2025

    Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received EU approval for Dyrupeg, a biosimilar. However, the company reported a 10.04% decline in Q3 FY25 net profit.
  • Aurobindo Pharma Secures EU Approval for Dyrupeg - 05 Apr, 2025

    Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received EU marketing authorization for Dyrupeg™, a pegylated filgrastim biosimilar. This approval enhances Aurobindo's biosimilar portfolio in Europe, providing a cost-effective treatment option for patients with low white blood cell counts.
  • Aurobindo Pharma Shares Plummet Amid Tariff Concerns - 04 Apr, 2025

    On April 4, 2025, Aurobindo Pharma's shares dropped significantly, falling up to 10% due to U.S. President Trump's remarks about impending tariffs on pharmaceutical imports.
  • Aurobindo Pharma Shares Surge After Tariff Exemption - 03 Apr, 2025

    Aurobindo Pharma's stock jumped 7.36% on April 3, 2025, following the U.S. administration's exemption of pharmaceuticals from reciprocal tariffs, benefiting the company's significant U.S. revenue exposure.
  • Aurobindo Pharma Faces Potential Tariff Challenges - 02 Apr, 2025

    Aurobindo Pharma may experience margin pressure due to potential tariffs of up to 35% on exports, affecting its substantial revenue from the US market.

Insights on Aurobindo Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 10 quarters, 5.79K Cr → 8.13K Cr (in ₹), with an average increase of 3.7% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 817.38 Cr → 845.81 Cr (in ₹), with an average increase of 3.4% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, AUROPHARMA stock has moved up by 6.4%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 17.81% to 18.21% in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 143.9% return, outperforming this stock by 48.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 55.3% return, outperforming this stock by 40.3%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 51.82% of holdings in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 16.29% to 15.33% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 6.69% to 6.61% in Mar 2025 quarter

Aurobindo Pharma News

Stocks to Watch on April 25: Earnings and Developments

IndusInd Bank denied media reports that claimed it stopped acquiring new customers for its microfinance business. The bank said it had not received any directive from the RBI to pause operations and that it continues to serve microfinance clients.25 Apr, 2025 06:21 AM

Market Update: Key Stocks to Watch on April 25, 2025

IndusInd Bank denied reports suggesting it has stopped acquiring new customers in its microfinance segment, stating it has not received any directive from the RBI to do so.25 Apr, 2025 06:11 AM

Earnings Reports: Axis Bank, Tech Mahindra, SBI Cards, and More

The lender on Thursday denied reports suggesting it has stopped acquiring new customers in its microfinance segment, stating it has not received any directive from the Reserve Bank of India (RBI) to do so.24 Apr, 2025 10:09 PM
View More

Aurobindo Pharma Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹7,271.23Cr (-)₹7,491.92Cr (↑3.04%)₹7,457.65Cr (↓0.46%)₹7,646.21Cr (↑2.53%)₹7,893.15Cr (↑3.23%)
Net Income₹939.97Cr (-)₹907.35Cr (↓3.47%)₹918.22Cr (↑1.20%)₹816.95Cr (↓11.03%)₹845.57Cr (↑3.50%)
Net Profit Margin12.93% (-)12.11% (↓6.34%)12.31% (↑1.65%)10.68% (↓13.24%)10.71% (↑0.28%)
Value in ₹ crore
Details2021202220232024
Total Assets₹23,257.60Cr (-)₹21,644.77Cr (↓6.93%)₹25,114.05Cr (↑16.03%)₹25,201.43Cr (↑0.35%)
Total Liabilities₹7,332.99Cr (-)₹4,527.43Cr (↓38.26%)₹7,080.02Cr (↑56.38%)₹5,478.61Cr (↓22.62%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹2,201.38Cr (-)₹2,994.53Cr (↑36.03%)₹3,726.71Cr (↑24.45%)₹1,816.17Cr (↓51.27%)₹1,714.80Cr (↓5.58%)

Aurobindo Pharma Index Inclusions

S&P BSE MidCap Select

₹15,899.34

-0.29 (-46.69%)

BSE Mid-Cap

₹43,590.49

-0.16 (-69.87%)

BSE 200

₹10,993.55

-0.26 (-28.44%)

BSE Healthcare

₹42,929.75

0.55 (236.74%)

Nifty Midcap 50

₹15,513.80

-0.17 (-26.35%)

Nifty Healthcare

₹14,173.35

0.4 (56.1%)

Nifty 500

₹22,180.65

-0.26 (-56.95%)

NIFTY PHARMA

₹21,974.60

1.08 (235.65%)

S&P BSE 250 LargeMidCap

₹10,401.21

-0.27 (-27.69%)

S&P BSE 400 MidSmallCap

₹11,334.15

-0.09 (-9.8%)

Nifty Midcap 100

₹54,969.85

-0.13 (-71.25%)

S&P BSE 150 MidCap

₹15,145.83

-0.16 (-24.7%)

Nifty LargeMidcap 250

₹15,485.00

-0.24 (-36.85%)

Nifty Midcap 150

₹20,194.40

-0.17 (-34.65%)

Nifty Midcap Sel

₹12,243.05

-0.19 (-23.1%)

Nifty 200

₹13,480.20

-0.28 (-37.35%)

Nifty MidSmallcap 400

₹18,655.75

-0.13 (-24.05%)

BSE 500

₹34,880.67

-0.23 (-82.11%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Aurobindo Pharma Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
51.82%
0.00
Foreign Institutions
15.33%
0.00
Mutual Funds
18.21%
0.00
Retail Investors
6.61%
0.00
Others
8.03%
0.00

Aurobindo Pharma Key Indicators

Details20202021202220232024
Earning Per Share (₹)48.5491.0445.1832.954.09
Details20202021202220232024
Return On Equity %15.3821.498.816.9810.35
Details20202021202220232024
Return On Assets %14.2422.9412.237.6712.59
Details20202021202220232024
Book Value Per Share (₹)287.16374.29419.46458.1509.35

Aurobindo Pharma Valuation

Aurobindo Pharma in the last 5 years

  • Overview

  • Trends

Lowest (6.73x)

March 23, 2020

Today (21.05x)

April 24, 2025

Industry (54.50x)

April 24, 2025

Highest (27.59x)

December 21, 2023

LowHigh

Aurobindo Pharma Earnings and Dividends

  • Aurobindo Pharma Ltd Earnings Results

    Aurobindo Pharma Ltd’s net profit fell -9.66% since last year same period to ₹845.81Cr in the Q3 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 3.48% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Aurobindo Pharma Ltd Dividends February,2024

    In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.36%.

    Read More about Dividends

Aurobindo Pharma Technicals Summary

Bearish

Neutral

Bullish

Bullish

Aurobindo Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.

Aurobindo Pharma Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹73,699.36 Cr19.69%0.56₹3,168 Cr₹29,001 Cr
BUY₹15,129.56 Cr-2.79%0.52₹602 Cr₹2,851 Cr
HOLD₹88,573.75 Cr32.73%0.64₹3,854 Cr₹19,547 Cr
BUY₹63,877.50 Cr15.4%0.53NANA
BUY₹49,398.80 Cr20.4%0.56₹589 Cr₹3,453 Cr

About Aurobindo Pharma

Aurobindo Pharma Ltd is an Indian multinational pharmaceutical company incorporated in 1986. Aurobindo Pharma operates in several lines of business including APIs, generics, biosimilars, advanced drugs, and consumer healthcare.

The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.

Revenue: ₹7,893.15Cr as on December 2024 (Q4 24)
Net Profit: ₹845.57Cr as on December 2024 (Q4 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
OrganisationAurobindo Pharma
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Aurobindo Pharma Ltd

What is Aurobindo Pharma Ltd price today?

Aurobindo Pharma Ltd share price today stands at ₹1257.8, Open: ₹1246.8, Previous Close: ₹1246.8, High: ₹1278.6, Low: ₹1239.8, 52 Week High: ₹1592, 52 Week Low: ₹1010.

How to Buy Aurobindo Pharma Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Aurobindo Pharma Ltd shares

What are today's traded volumes of Aurobindo Pharma Ltd?

Today's traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 13.38L.

What is today's market capitalisation of Aurobindo Pharma Ltd?

Today's market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹73699.36Cr.

What is the 52 Week High and Low Range of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd (AUROPHARMA)
Price
52 Week High
₹1592
52 Week Low
₹1010

How much percentage Aurobindo Pharma Ltd is down from its 52 Week High?

Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1257.8. It is down -20.99% from its 52 Week High price of ₹1592

How much percentage Aurobindo Pharma Ltd is up from its 52 Week low?

Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1257.8. It is up 24.53% from its 52 Week Low price of ₹1010